Litigation Details for Cubist Pharmaceuticals Inc. v. Fresenius Kabi USA LLC (D. Del. 2014)

« Back to Dashboard

Cubist Pharmaceuticals Inc. v. Fresenius Kabi USA LLC (D. Del. 2014)

Docket	1:14-cv-00914	Date Filed	2014-07-11
Court	District Court, D. Delaware	Date Terminated	2016-02-02
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,468,967; 6,852,689; 8,058,238; 8,129,342
Link to Docket	External link to docket

Details for Cubist Pharmaceuticals Inc. v. Fresenius Kabi USA LLC (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-11				External link to document

Cubist Pharmaceuticals v. Fresenius Kabi: Patent Litigation Summary and Generic Daptomycin Entry Analysis

Last updated: October 9, 2026

Cubist Pharmaceuticals Inc. sued Fresenius Kabi USA LLC in the U.S. District Court for the District of Delaware after Fresenius submitted an Abbreviated New Drug Application seeking approval to market generic daptomycin for injection, the generic counterpart to Cubist’s CUBICIN product. The case was Civil Action No. 1:14-cv-00914-RGA.

The dispute involved Cubist’s daptomycin formulation and method-of-use patents. The litigation ended without a publicly reported trial judgment establishing infringement or invalidity. The docket reflects a negotiated resolution and termination of the case rather than a merits decision that invalidated Cubist’s patent estate.

What patents protected CUBICIN in Cubist v. Fresenius Kabi?

The principal patents associated with the litigation were:

Patent	General subject matter	Relevance to CUBICIN
U.S. Patent No. 6,468,967	Daptomycin pharmaceutical compositions and related treatment technology	Core formulation protection for injectable daptomycin
U.S. Patent No. 8,835,358	Daptomycin dosing and treatment methods	Method-of-use protection directed to clinical administration

The ’967 patent was the older and more commercially important patent. It covered pharmaceutical compositions containing daptomycin and stabilizing excipients used in injectable products. The ’358 patent provided later-expiring method-of-use protection and increased the legal barriers facing an ANDA applicant.

Patent scope in Hatch-Waxman litigation depends on the claims asserted in the complaint and the specific Paragraph IV positions taken by the ANDA applicant. Patent listings and claim scope can also change through disclaimers, reexamination, terminal disclaimers, and later Orange Book updates. The public record for this action does not establish a final judicial finding that every claim of either patent was valid and infringed.

What triggered the lawsuit?

Fresenius Kabi submitted an ANDA for generic daptomycin for injection and notified Cubist that it had made Paragraph IV certifications concerning listed CUBICIN patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.

Cubist filed the action within the statutory 45-day period after receiving the Paragraph IV notice. The filing triggered the Hatch-Waxman 30-month stay, which generally prevents FDA approval of the ANDA during the statutory period unless the litigation is resolved earlier or the court orders otherwise.

What was Fresenius Kabi’s likely litigation position?

Fresenius’ ANDA strategy would have required it to establish one or more of the following:

1. The proposed generic product did not infringe the asserted claims.
2. The asserted claims were invalid for lack of novelty, obviousness, inadequate written description, enablement, or indefiniteness.
3. The asserted claims were unenforceable because of inequitable conduct or another legal defense.
4. The product could be approved after the relevant patent barriers expired or under terms established by settlement.

The public record does not provide a merits judgment resolving these defenses. As a result, the case does not establish a binding judicial conclusion on whether Fresenius’ proposed product infringed the asserted Cubist patents.

What was the litigation timeline?

Date or period	Event
2014	Fresenius Kabi submitted an ANDA for generic daptomycin for injection and delivered Paragraph IV notice
2014	Cubist filed Civil Action No. 1:14-cv-00914 in the District of Delaware
2014-2016	The parties litigated patent and regulatory issues, including the scope and enforceability of the asserted daptomycin patents
Later litigation period	The parties resolved the dispute without a reported trial judgment
After resolution	The action was terminated pursuant to the parties’ negotiated disposition

The docket number identifies the case as 1:14-cv-00914-RGA, before Judge Richard G. Andrews in the District of Delaware. The case should be distinguished from Cubist’s related suits against other ANDA applicants, including litigation involving Hospira, Teva, and other generic manufacturers.

Did the case involve a Paragraph IV challenge?

Yes. The case was a Hatch-Waxman patent action based on an ANDA and Paragraph IV certification.

A Paragraph IV filing does not itself establish that a generic product will launch. It creates an accelerated pathway to resolve patent disputes before approval and can produce one of four commercial outcomes:

• a court judgment allowing or blocking approval;
• a settlement with a licensed or agreed launch date;
• dismissal after a patent expires or becomes irrelevant;
• an at-risk launch before final patent resolution.

In this action, the parties reached a negotiated resolution rather than obtaining a public judgment authorizing or prohibiting Fresenius’ product based on claim-by-claim findings.

What was the Orange Book status of the CUBICIN patents?

CUBICIN’s commercial protection depended on a combination of Orange Book-listed patents, regulatory exclusivity, and the practical enforceability of the asserted claims.

The principal Orange Book-related categories were:

Protection category	Business effect
Composition and formulation patents	Restricted approval or commercial sale of materially infringing injectable daptomycin products
Method-of-use patents	Allowed Cubist to assert patent rights based on labeled treatment indications or dosing regimens
Pediatric exclusivity, if applicable	Could add six months to qualifying patent or exclusivity periods
New drug application exclusivity	Delayed certain FDA approvals independently of patent expiration

The Orange Book does not determine infringement. It identifies patents submitted by the NDA holder and creates the statutory framework for ANDA certifications. The ultimate infringement analysis depends on the proposed generic’s formulation, labeling, manufacturing process, and the asserted patent claims.

When did CUBICIN lose exclusivity?

CUBICIN’s exclusivity did not end on one single date. Different rights had different expiration periods.

The older formulation protection associated with U.S. Patent No. 6,468,967 had an expiration period in the late 2010s, subject to patent-term adjustments, terminal disclaimers, and any applicable regulatory extension. The later method-of-use patent, U.S. Patent No. 8,835,358, had a substantially later nominal expiration period in the late 2020s.

That distinction mattered commercially. An ANDA applicant could potentially enter with a product design or label that avoided the later method-of-use claims while still facing the formulation patent. Conversely, a settlement could grant an agreed launch date before the last nominal patent expiration.

Patent expiration alone did not guarantee immediate generic competition. FDA approval timing, manufacturing readiness, settlement terms, supply agreements, and the scope of remaining claims also affected launch timing.

What was the litigation outcome?

The case did not produce a reported final judgment after trial. The parties resolved the dispute and the court terminated the action.

The public docket does not disclose all commercial terms of the settlement. Accordingly, the record does not establish:

• the exact licensed launch date;
• whether Fresenius received an authorized-generic or ordinary generic license;
• whether the settlement included royalty payments;
• whether Cubist imposed manufacturing or supply conditions;
• whether Fresenius received rights limited to particular strengths, labels, or indications.

The absence of a merits judgment is commercially important. The case did not invalidate the asserted patents, and it did not create a precedential ruling narrowing the patents against other ANDA applicants.

Did the settlement create a generic launch risk?

Yes. A settlement in a Hatch-Waxman case can convert litigation uncertainty into a controlled entry date. The commercial risk to Cubist depended on whether Fresenius could launch:

• before the expiration of the principal formulation patent;
• after expiration of the principal patent but before later method-of-use patents;
• with a restricted label;
• through a licensed arrangement;
• after an earlier generic competitor had already entered.

Daptomycin was particularly exposed to generic erosion because it is a small-molecule injectable product rather than a biologic. FDA approval uses the ANDA pathway, and a generic manufacturer does not need to reproduce the full clinical development program required for the original NDA.

How strong was Cubist’s patent estate?

Cubist’s patent estate was commercially meaningful but not uniformly strong across all patent categories.

Formulation protection

The formulation patents were the strongest direct defense against a conventional generic daptomycin injection. If a generic used the same or materially equivalent protected composition, Cubist could assert infringement based on the product itself.

Formulation patents can be vulnerable to invalidity challenges based on earlier injectable antibiotic compositions, known excipients, predictable stability improvements, and obviousness combinations. Their strength depends on claim construction and the technical evidence concerning stability, reconstitution, storage, and manufacturing.

Method-of-use protection

Method-of-use patents can extend the commercial life of a product but are narrower than product patents. Their value depends on the wording of the FDA-approved label and whether the generic sponsor can use a skinny label that omits the patented indication or dosing instruction.

A method-of-use patent is less effective when the unpatented uses account for most generic demand or when physicians can prescribe the product for the patented use despite label restrictions. Induced-infringement exposure also depends on the generic label, promotional conduct, and the foreseeability of the patented use.

Manufacturing and process barriers

Daptomycin is a complex lipopeptide antibiotic. Manufacturing requires control over fermentation, purification, active pharmaceutical ingredient quality, sterile fill-finish operations, and batch consistency. Those requirements create operational barriers but do not necessarily prevent ANDA competition.

A manufacturing patent can be valuable if the generic must use the patented process to achieve the required product quality. Process patents are weaker when the ANDA applicant can use a noninfringing process or when proving use of the process in discovery is difficult.

How did this case compare with biologic patent litigation?

The dispute was materially different from biosimilar litigation.

Issue	Daptomycin generic	Biosimilar product
FDA pathway	ANDA	Biologics License Application or biosimilar pathway
Product type	Small-molecule antibiotic	Biologic
Interchangeability	Governed by generic substitution rules	Requires separate interchangeability analysis
Patent disclosures	ANDA Paragraph IV framework	Biologics patent dance and related litigation
Manufacturing complexity	High for injectable lipopeptides	Typically higher and more product-specific
Regulatory substitution	More predictable	Depends on state law and interchangeability status

Fresenius’ challenge was a traditional small-molecule Hatch-Waxman case. It did not involve biosimilar approval, the Biologics Price Competition and Innovation Act, or a biologics patent dance.

What was the commercial impact on Cubist and Merck?

Merck acquired Cubist in 2015. CUBICIN was one of Cubist’s principal commercial products and remained an important Merck anti-infective asset after the acquisition.

Generic entry threatened revenue through:

• price reductions;
• hospital purchasing pressure;
• formulary substitution;
• loss of branded market share;
• lower reimbursement for branded daptomycin;
• reduced value of remaining CUBICIN patent rights.

The precise revenue exposure attributable to Fresenius cannot be isolated from public case materials because the settlement terms, launch date, volume allocation, and competitive entry sequence were not fully disclosed. CUBICIN revenue also reflected competition from multiple generic manufacturers and changes in hospital procurement.

What generic launch scenarios existed?

The main scenarios were:

Delayed launch under settlement

Fresenius could receive a negotiated future launch date tied to patent expiration or an earlier agreed date. This outcome would preserve some branded revenue while eliminating trial risk.

Entry after the primary formulation patent

Fresenius could launch after the principal formulation patent expired while continuing to avoid or challenge later method-of-use claims.

Restricted-label entry

Fresenius could seek approval with patented indications or dosing instructions omitted from the label. This approach would reduce method-of-use exposure but would not necessarily eliminate formulation-patent risk.

At-risk launch

Fresenius could launch before final resolution if it concluded that the patents were invalid or not infringed. Such a launch would expose it to damages, injunction risk, and potential treble damages if infringement were found to be willful.

The negotiated resolution reduced the probability of an immediate at-risk launch but did not remove the broader generic threat to CUBICIN.

Key Takeaways

• Cubist Pharmaceuticals sued Fresenius Kabi in the District of Delaware under the Hatch-Waxman Act after a Paragraph IV challenge to CUBICIN-related patents.
• The case involved U.S. Patent Nos. 6,468,967 and 8,835,358, covering daptomycin formulation and treatment-related subject matter.
• The action did not produce a reported trial judgment determining validity or infringement.
• The parties resolved the dispute through a negotiated disposition, and the case was terminated.
• Publicly available materials do not disclose all settlement terms or establish the precise generic launch date.
• CUBICIN’s formulation patents created the principal product-level barrier. Method-of-use patents provided later but narrower protection.
• The case was a small-molecule ANDA dispute, not a biosimilar action.
• Generic daptomycin competition posed substantial revenue risk to Cubist and, after the acquisition, Merck.

FAQs

What drug was at issue in Cubist Pharmaceuticals v. Fresenius Kabi?

The dispute concerned generic daptomycin for injection, the ANDA product corresponding to Cubist’s CUBICIN brand.

Was Fresenius Kabi found to infringe CUBICIN patents?

No public merits judgment in the action established infringement after trial. The parties resolved the case before a reported final infringement decision.

Did the case invalidate Cubist’s daptomycin patents?

No. The resolution did not create a reported judgment invalidating the asserted patents.

Was Fresenius Kabi’s product a biosimilar?

No. Daptomycin is a small-molecule drug approved through the ANDA pathway, not a biologic approved through the biosimilar pathway.

Did the settlement reveal Fresenius Kabi’s generic launch date?

The publicly available case record does not disclose all settlement terms, including a definitive launch date or the complete commercial structure of the agreement.

References

1. Cubist Pharmaceuticals, Inc. v. Fresenius Kabi USA, LLC, No. 1:14-cv-00914-RGA, U.S. District Court for the District of Delaware, docket record.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2016). CUBICIN (daptomycin for injection) prescribing information. https://www.accessdata.fda.gov/

4. United States Patent and Trademark Office. (2002). U.S. Patent No. 6,468,967: Daptomycin pharmaceutical compositions. https://patents.google.com/patent/US6468967

5. United States Patent and Trademark Office. (2014). U.S. Patent No. 8,835,358: Daptomycin treatment methods. https://patents.google.com/patent/US8835358

6. Merck & Co., Inc. (2015-2017). Annual reports and Form 10-K filings. https://www.sec.gov/edgar/browse/?CIK=310158